<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095078</url>
  </required_header>
  <id_info>
    <org_study_id>Ancillary Home-Care SIMEOX</org_study_id>
    <nct_id>NCT04095078</nct_id>
  </id_info>
  <brief_title>Ancillary Home Airway Clearance in CF Patients ( HomeCareSIMEOX )</brief_title>
  <official_title>Efficiency and Acceptability of SIMEOX® Used Autonomously at Home for Bronchial Clearance in Patients With Cystic Fibrosis: Ancillary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Physio-Assist</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icadom</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Physio-Assist</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regular bronchial clearance is essential in patients with cystic fibrosis for their bronchial&#xD;
      health. SIMEOX® (Physio-Assist, Aix en Provence, France) is an innovative medical device for&#xD;
      the drainage of the bronchial tree. By changing the rheological properties of mucus, SIMEOX®&#xD;
      helps to mobilize secretions and assists their transport to the upper airways. This&#xD;
      technology is based on fundamental research on bronchial mucus rheology. At the present time,&#xD;
      SIMEOX® device is mainly used over a short period at the time or after an exacerbation in&#xD;
      healthcare structures (hospitals, physiotherapy practices, postcare, and rehabilitation&#xD;
      units, etc…). The clinical effects observed in the short term encourages long-term autonomous&#xD;
      use by the patients themselves. The overall objective of this study is to evaluate the&#xD;
      efficiency and acceptability of SIMEOX® used at home by the patient himself for bronchial&#xD;
      clearance in patients with cystic fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, controlled, multicenter trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary static hyperinflation assessed by residual volume</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Relative variation in Pulmonary residual volume in the SIMEOX® treated group versus control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use assessed by the duration of use of SIMEOX® device</measure>
    <time_frame>During 3 months of use</time_frame>
    <description>Assess the duration of uses of the device SIMEOX by the patient in the SIMEOX® treated group to assess the use by patient of the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inspiratory capacity</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Relative variation of Inspiratory capacity in liter in the SIMEOX® treated group versus control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual functional capacity (RFC)</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Relative variation of Residual functional capacity (RFC) in liter in the SIMEOX® treated group versus control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lung capacity (TLC)</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Relative variation of Total lung capacity (TLC) in liter in the SIMEOX® treated group versus control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Pulmonary Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>SIMEOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use the device for 3 months in addition to usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SIMEOX</intervention_name>
    <description>Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX</description>
    <arm_group_label>SIMEOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  one of the 56 first patients of HOME-CARE SIMEOX study&#xD;
&#xD;
          -  same criteria as HOME-CARE SIMEOX study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  same criteria as HOME-CARE SIMEOX study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boubou Camara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUGA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Borges</last_name>
    <phone>0476747703</phone>
    <phone_ext>+33</phone_ext>
    <email>l.borges@agiradom.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Christian Jean-Christian, PHD</last_name>
    <phone>04.56.38.86.56</phone>
    <phone_ext>+33</phone_ext>
    <email>j.borel@agiradom.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grenoble University Hospital : pneumo-pediatric department</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle PIN, MD</last_name>
      <email>IPin@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline TOURNEGROS</last_name>
      <email>Ctournegros@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Isabelle PIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cathy LLERENA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble University-Affiliated Hospital : Pneumology department</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boubou Camara, MD</last_name>
      <phone>+33 476765846</phone>
      <email>bcamara@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie Jondot</last_name>
      <email>mjondot@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Boubou Camara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastien Quetant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montpellier Hospital Center</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Nice University-Affiliated Hospital : Pneumology department</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Leroy, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jennifer Griffonnet</last_name>
      <phone>+33 4 92 03 82 81</phone>
      <email>griffonnet.j@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sylvie Leroy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johana Pradelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michèle Benhayoun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nice University-Affiliated Hospital : Pneumo-pediatric department</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aline Joulie</last_name>
      <phone>+33 4.92.03.05.20</phone>
      <email>joulie.a@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Carole Piccini Bailly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bronchial clearance</keyword>
  <keyword>cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

